Method for differentiating between lung squamous cell carcinoma and lung adenocarcinoma
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Sep 29, 2020
Grant Date -
Mar 16, 2017
app pub date -
Mar 11, 2015
filing date -
Mar 12, 2014
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Provided is an approach for differentially determining the histological type of a lung cancer lesion objectively and rapidly with high accuracy. A method for differentially assessing a lesion in a lung cancer patient as squamous cell carcinoma or adenocarcinoma, comprising a step of measuring an expression level of an expression product of at least one DNA comprising a transcription start site in a biological sample collected from the lesion, wherein the DNA comprises a base at an arbitrary position in the transcription start site and at least one or more bases located immediately downstream thereof in any of nucleotide sequences represented by SEQ ID NOs: 1 to 213, and the transcription start site is a region wherein both ends thereof are defined by the first base and the 101st base counted from the 3′ end in any of the nucleotide sequences represented by SEQ ID NOs: 1 to 213.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully